Welcome : Guest

Nektar Therapeutics (USA) - Facts, Figures and Analytical Insights

Abstract

This report presents quick facts about Nektar Therapeutics, which is principally a Biopharmaceutical Company. Illustrated with 89 tables, the report showcases the company's sales performance, key markets and market position as against its competitors operating in the industry.

Code: PCP-04262
Price: $3500
Company Type: Public
Pages: 92
Date: November 2016
Market Data Tables: 89

 NOTE : Select the checkbox below, and click Add to Cart button to add this report to your shopping cart.
Table 1: Nektar Therapeutics’s Sales by Geographic Region Worldwide (2014-2015) in Percentage for United States, and Europe......2
Cancer Drugs......5
Table 2: Oncology/Hematology Drugs Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Blood Cell Factors, Chemopreventatives, Chemotherapeutics, Mabs, Targeted Therapies, and Others......5
Table 3: Oncology Drug Market by Region Worldwide (2015) - Percentage Share Breakdown by Value for European Union Five, Japan, US and Others......6
Cancer Market......7
Table 4: Cancer Care Expenditure by Site Worldwide (2015) - Percentage Share Breakdown for Breast, Colorectal, Lymphoma, Lung, Prostate and Others......7
Table 5: Cancer Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Heme, Lung, Prostate, and Others......8
Table 6: Oncology Market by Cancer Type Worldwide (2015) - Percentage Share Breakdown by Value for Breast Cancer, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, and Others......9
Table 7: Clinical Oncology Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for US, and Others......10
Table 8: Hereditary Oncology Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for US, and Others......11
Table 9: Cancer Market by Type in China (2015) - Percentage Share Breakdown by Value for Breast, Colorectal, Esophagus, Liver, Lung, Stomach and Others......12
Table 10: Oncology Market by Category in China (2015) - Percentage Share Breakdown by Value for Anti- Tumor Agents, Hormone Therapy, Immuno Suppresants and Immunostimulants......13
Table 11: Oncology Market by Segment in the US (2015) - Percentage Share Breakdown by Value for Solid Tumor and Others......14
Cancer Patients......15
Table 12: Breast Cancer Diagnoses by Hospital Type in the US (2015) - Percentage Share Breakdown by Volume for Community, Comprehensive, Teaching and Research, and Others......15
Table 13: No. of Colorectal Cancer Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......16
Table 14: No. of Invasive Breast Cancer Patients by Category Worldwide (2015) - Percentage Market Share Breakdown for Stage I and Stage II-III......17
Table 15: No. of Primary Liver Cancer Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......18
Table 16: No. of Chronic Lymphocytic Leukemia (CLL) (1L) Patients by Category Worldwide (2015) - Percentage Market Share Breakdown for Imbruvica PCYC, Rituxan, Gazyva ROG, and Others......19
Table 17: No. of Cutaneous Melanoma Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......20
Table 18: No. of Ocular Melanoma Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......21
Table 19: Female Mortality by Cancer Type in China (2015) - Percentage Market Share Breakdown by Volume for Lung, Breast, Colon, Rectum and Anus, Intestine, Liver, and Others......22
Table 20: Male Mortality by Cancer Type in China (2015) - Percentage Market Share Breakdown by Volume for Colon, Colon, Rectum and Anus, Intestine, Liver, Lung, and Others......23
Table 21: No. of Chronic Lymphocytic Leukemia (CLL) (1L) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......24
Table 22: No. of Chronic Lymphocytic Leukemia (CLL) (R/R) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......25
Table 23: No. of Cancer Patients by Type in the US (2015) - Percentage Market Share Breakdown for Colorectal Cancer (CRC), Melanoma, Non-Squamous Non-Small-Cell Lung Cancer (NSCLC), Ovarian, Prostate, Renal Cell Carcinoma (RCC), and Squamous Non-Small-Cell Lung Cancer (NSCLC)......26
Table 24: Number of Cancer Patients by Type in the US (2015) - Percentage Share Breakdown by Volume for Bladder Cancer, Breast Cancer (Female), Colon and Rectum Cancer, Endometrial Cancer, Kidney and Renal Pelvis Cancer, Lung and Bronchus Cancer, Melanoma of the Skin, Non-Hodgkin Lymphoma, Prostate Cancer, and Thyroid Cancer......27
Table 25: No. of Cancer Patients Death by Type in the US (2015) - Percentage Share Breakdown for Breast, Colorectal, Lung, Melanoma, and Prostate......28
Table 26: New Patients with Cancer by Site in the US (2015) - Percentage Market Share Breakdown by volume for Colorectal, Lung and Bronchus, Melanoma, Pancreas, and Others......29
Table 27: Number of Cancer Patients by Type Worldwide (2015) - Percentage Share Breakdown by Volume for Bladder, Breast, Cervix Uteri, Colorectum, Liver, Lung, Non-Hodgkin lymphoma, Oesophagus, Prostate, and Stomach......30
Table 28: No. of Bladder Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Invasive Patients, and Non-Invasive Patients......31
Table 29: No. of Invasive Breast Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Stage I and Stage II-III......32
Table 30: New Patients with Cancer in Stage 3/4 by Site in the US (2015) - Percentage Market Share Breakdown by Volume for Colorectal, Lung and Bronchus, Pancreas and Others......33
Table 31: No. of Solid Cancer Tumor Patients by Type Worldwide (2015) - Percentage Share Breakdown for Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma, and Prostate Cancer......34
Table 32: No. of Non Small Cell Lung Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Stage I, Stage II-III, Stage III-IV, and Undiagnozed......35
Cervical Cancer......36
Table 33: Cervical Cancer Market by HPV Type in England (2015) - Percentage Share Breakdown by Value for HPV 16, HPV 18, HPV 33, HPV 45, and Others......36
Table 34: Cervical Cancer Market by HPV Type in Europe (2015) - Percentage Share Breakdown by Value for HPV 16, HPV 18, HPV 31, HPV 33, and Others......37
Hematological Cancer......38
Table 35: Hematological Cancer by Category Worldwide (2015) - Percentage Market Share Breakdown by Value Sales for Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), and Non-Hodgkin’s Lymphoma (NHL)......38
Skin Cancer......39
Table 36: Skin Cancer by Type Worldwide (2015) - Percentage Market Share Breakdown by Volume for Basal Cell Carcinomas, Melanoma, and Squamous Cell Carcinomas......39
Cancer-Associated Mucositis......40
Table 37: Cancer-Associated Mucositis Market by Activity Worldwide (2015) - Percentage Share Breakdown by Value for Breast, Colorectal, Head and Neck, Non-Small Cell Lung cancer and Others......40
Chronic Myelogenous Leukemia (CML)......41
Table 38: Chronic Myelogenous Leukemia (CML) Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for Asia-Pacific, Canada, European Union, Japan, USA, and Others......41
Multiple Myeloma......42
Table 39: Multiple Myeloma by Age Group Worldwide (2015) - Percentage Share Breakdown by No. of New Cases for 45-54, 55-64, 65-74, 75-84, >84, and Others......42
Table 40: Multiple Myeloma Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Kyprolis AMGN, Pomalyst CELG, Revlimid CELG, Thalomid CELG, and Velcade TKD/JNJ......43
Hepatitis C......44
Table 41: Hepatitis C Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Immuno Modulator, Polymerase Inhibitor, Protease Inhibitors, and Others (Includes Ribavirin)......44
Table 42: Hepatitis C Market by Genotype Worldwide (2015) - Percentage Share Breakdown by Value for Genotype 1, Genotype 2 and Others......45
Table 43: Hepatitis C Virus Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Immuno-Modulator, Polymerase Inhibitor, Protease Inhibitors, Ribavirin, and Others......46
Table 44: Hepatitis C Virus Market by Patient Conditions in Europe (2015) - Percentage Share Breakdown by Value for Diagnosed, Prevalence, Under Care and Others......47
Table 45: No. of Hepatitis C Virus (HCV) Patients by Category in European Union (EU) (2015) - Percentage Market Share Breakdown for GT1, and Non-GT1......48
Table 46: Hepatitis C Virus Market by Patient Conditions in the US (2015) - Percentage Share Breakdown by Value for Diagnosed, Prevalence, Under Care and Others......49
Table 47: Health Insurance for Hepatitis C Virus (HCV) by Type in the US (2015) - Percentage Market Share Breakdown by Value for Commercial, Dual (Medicare and Medicaid), Medicaid, Medicare (Non- Dual), Prison, Uninsured, and Veteran Affairs......50
Table 48: No. of Hepatitis C Virus (HCV) Patients by Category in the US (2015) - Percentage Market Share Breakdown for GT1 HCV, GT2/3 HCV, and Others......51
Rheumatoid Arthritis......52
Table 49: Rheumatoid Arthritis Market by Product Type Worldwide (2015) - Percentage Share Breakdown by Value Sales for ENBREL, HUMIRA, REMICADE, and Others......52
Psoriasis......53
Table 50: Psoriasis Disease by Type Worldwide (2015) - Percentage Market Share Breakdown by Volume for Palmoplantar Psoriasis, Plaque Psoriasis, Psoriasis of Mucous Membranes, Psoriatic Arthritis, and Pustular Psoriasis......53
Migraine Drugs......54
Table 51: Migraine Drugs Market by Category in the US (2015) - Percentage Share Breakdown by Prescriptions for Amerge Generic (Naratriptan), Imitrex Generic (Sumatriptan), Maxalt Generic (Rizatriptan), Relpax (Pfizer), and Zomig Generic (Zolmitriptan)......54
Hemophilia......55
Table 52: Hemophilia Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Hemophilia A, Hemophilia B, Inhibitor, and Von Willebrand Disease......55
Table 53: Hemophilia Diagnosis and Treatments Rates by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for Diagonised, Pristine Joints, Prophylactic, Treated, and Others......56
Table 54: Haemophilia by Severity Stage Worldwide (2015) - Percentage Market Share Breakdown by No. of Patients for Mild, Moderate and Severe......57
Table 55: Haemophilia Patient Population by Category Worldwide (2015) - Percentage Market Share Breakdown by Volume for Haemophilia A (Factor VIII Deficiency) and Haemophilia B (Factor IX Deficiency)......58
Table 56: Continuous Prophylaxis (Moderate) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......59
Table 57: Continuous Prophylaxis Treatment (Severe) for Hemophilia A Patients by Age Group Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......60
Table 58: On-Demand (Moderate Patient) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......61
Table 59: On-Demand (Severe Patient) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......62
Table 60: Haemophilia B - Recombinant (Benefix) Sales by Region Worldwide (2015) - Percentage Market Share Breakdown by Value for Emerging Markets, Europe, US, and Others......63
Table 61: Immune Tolerance Therapy (Patient) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......64
Table 62: Intermittent Prophylaxis (Moderate Patient Equivalent) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......65
Table 63: Intermittent Prophylaxis (Severe Patient Equivalent) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......66
Table 64: U.S. Hemophilia Market Patients Treated/Year (2014)......67
Immunology......68
Table 65: Immunology Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value for Dermatology, Gastroenterology, and Rheumatology......68
Wet Age-Related Macular Degeneration (AMD) Anti Vascular Endothelial Growth Factor (VEGF)......69
Table 66: Wet Age-Related Macular Degeneration (AMD) Anti Vascular Endothelial Growth Factor (VEGF) Market by Segment in the US (2015) - Percentage Share Breakdown by Value for Avastin, Eylea, and Lucentis......69
Table 67: Blindness Market by Category in Germany (2015) - Percentage Market Share Breakdown by Value for Age-Related Macular Degeneration, Cataract, Glaucoma, and Others......70
Cystic Fibrosis (CF) Patient Population......71
Table 68: Cystic Fibrosis (CF) Patient Population by Region Worldwide (2015) - Percentage Share Breakdown by Value for Australia, Canada, Rest of Europe, United Kingdom and USA......71
Table 69: Drugs for Treatment of Cystic Fibrosis Market Worldwide (2015) in US$ Million......72
Systemic Lupus Erythematosus with Benlysta......73
Table 70: Systemic Lupus Erythematosus with Benlysta Market by Category in the US (2015) - Percentage Share Breakdown by Value for Mild Systemic Lupus Erythematosus (excluded in target population), Moderate Systemic Lupus Erythematosus, and Severe Systemic Lupus Erythematosus......73
Chronic Pain......74
Table 71: No. of Population with Chronic Pain by Age in the US (2015) - Percentage Share Breakdown by Volume for 18 & over and 18 & Under......74
Table 72: No. of Population with Chronic Pain by Type in the US (2015) - Percentage Breakdown by Volume for Back Pain and Other Pain......75
Table 73: Spinal Cord Stimulation (SCS) for Chronic Pain by Category in the US (2015) - Percentage Share Breakdown by Volume for Back Pain alone, Leg & Back Pain, Leg Pain alone and Upper Extremity Pain......76
Table 74: Chronic Pain in Adults by Pain Type in the US (2015) - Percentage Share Breakdown by Volume for Knee Pain, Low Back Pain, Serve Headache or Migraine......77
Table 75: Spinal Cord Stimulation Systems for Chronic Pain (incl. back pain, leg pain and back/leg pain) Market Worldwide (2015) in US$ Million......78
Table 76: No. of People with Chronic Pain in the US (2015-2020) in Million......79
Cancer Drugs......80
Table 77: Market Shares of Leading Oncology Product Manufacturers Worldwide (2015) - Percentage Breakdown by Value for Fresenius SE & Co., and Others......80
Table 78: Market Shares of Leading Oncology/Hematology Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for AbbVie, Amgen, Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., Novartis AG, Pfizer, Inc., Sanofi S.A., and Others......81
Table 79: Market Shares of Leading Oncology Drug Manufacturers in China (2015) - Percentage Share Breakdown by Value for Astrazeneca, Jiangsu Hengrui Medicine Co., Ltd., Roche Group and Others......82
Table 80: Anti-Cancer Drugs Market by Product Type in China (2015) - Percentage Share Breakdown by Value for Anastrozole, Capecitabine, Cetuximab, Compound kushen, Docetaxel, Epirubicin, Erlotinib, Gefitinib, Gemcitabine, Goserelin, Interferon α-2a, Interferon α-2b, Irinotecan, Kangai, Lentinan, Letrozole, Oxaliplatin, Paclitaxel, Pemetrexed, Pidotimod, RhG-CSF, RhIL-2, Rituximab, Sorafenib, Sshenqi Fuzheng, Thymopentin, Thymosin a1, Trastuzmmab, Triptorelin, TS-1, and Others......83
Table 81: Anti-Cancer Drugs Market by Type in China (2015) - Percentage Share Breakdown by Value for Alkylating Agents, Antibiotics, Antimetabolites, Hormonal Agents, Immunostimulant, Plant Alkaloids, and Others......84
Breast Cancer Drugs......85
Table 82: Market Shares of Leading Breast Cancer Drugs by Value Sales in China (2014) - Percentage Breakdown for Alkylating Agents, Antimetabolite, Antitumor Antibiotics, Antitumor Antihormone, Antitumor Botanicals, Monoclonal Antibodies, Targeted Small Molecule Agents, and Others......85
Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL)......86
Table 83: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib, Idelalisib and Others......86
Relapsed/Refractory (RR) Indolent Non-Hodgkin's Lymphoma (iNHL)......87
Table 84: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory (RR) Indolent Non-Hodgkin's Lymphoma (iNHL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib, Idelalisib and Others......87
Table 85: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma (R/R- aNHL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib and Others......88
Psoriasis......89
Table 86: Market Shares of Leading Drugs for Treatment of Psoriasis Worldwide (2015) - Percentage Share Breakdown by Value for Enbrel, Humira, Remicade, Stelara and Others......89
Anti-Infectives......90
Table 87: Market Shares of Leading Anti-Infective Product Manufacturers Worldwide (2015) - Percentage Breakdown by Value for Bayer AG, Merck & Co., Inc., Vétoquinol S.A., Virbac S.A., Zoetis, Inc. and Others......90
Table 88: Nektar Therapeutics Sales by Country Worldwide (2013) in Percentage for United States and Europe......91
Table 89: Nektar Therapeutics’ Revenue by Category Worldwide (2011-2013) in US$ Thousands for Product Sales, Royalty Revenue, Non-Cash Royalty Revenue Related to Sale of Future Royalties, License, Collaboration and Other Revenue......92